These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S. J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [Abstract] [Full Text] [Related]
23. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative. JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [Abstract] [Full Text] [Related]
26. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Arch Neurol; 2009 Apr; 66(4):448-57. PubMed ID: 19364929 [Abstract] [Full Text] [Related]
27. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Förstl H, Kurz A, Alexopoulos P. Neurology; 2011 Jul 05; 77(1):35-8. PubMed ID: 21700579 [Abstract] [Full Text] [Related]
30. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Nägga K, Gottfries J, Blennow K, Marcusson J. Dement Geriatr Cogn Disord; 2002 Jul 05; 14(4):183-90. PubMed ID: 12411760 [Abstract] [Full Text] [Related]
31. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A. J Alzheimers Dis; 2014 Jul 05; 42(1):157-67. PubMed ID: 24820015 [Abstract] [Full Text] [Related]
33. Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J. J Neural Transm (Vienna); 2007 Jul 05; 114(5):621-8. PubMed ID: 17245538 [Abstract] [Full Text] [Related]
34. Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio. Slemmon JR, Shapiro A, Mercken M, Streffer J, Romano G, Andreasen N, Zetterberg H, Blennow K. J Neurochem; 2015 Dec 05; 135(5):1049-58. PubMed ID: 26332787 [Abstract] [Full Text] [Related]
35. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Arch Neurol; 1999 Jun 05; 56(6):673-80. PubMed ID: 10369305 [Abstract] [Full Text] [Related]